Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIMOC
2024-513647-86-00Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of tocilizumab, secukinumab, anakinra, adalimumab, rituximab and 1 more in severe resistant inflammatory multi-organ disease, Immune disorder and Skin and connective tissue disease (6 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Composite clinical and biological response at month 6. Started Sep 2024; status: completed.
02
Drugs
03
Conditions
severe resistant inflammatory multi-organ diseaseImmune disorderSkin and connective tissue disease
Beyond the preview
Go deeper on 2024-513647-86-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513647-86-00.